Answers are grounded in this paper and cite their sources.
Additional studies to optimize treatment for this important subset of patients are needed. A uniform definition of unfit patients will lead to more uniform clinical trials, enhanced ability to interpret the results of these trials, and a greater likelihood of developing a viable strategy for regulatory approval.
No takes yet. Share an insight, caveat, or question.
Galsky et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: